Chiron's Conservative Cash Play
Executive Summary
Two years after selling off its diagnostics business, Chiron has finally decided how to spend some of the money: it bought Pathogenesis for about $700 million. The move brings one small marketed product, and complementary research capacity that promises mostly longer-term benefit for Chiron's interests in infectious diseases. Analysts and investors aren't thrilled by the conservative move, but they're not bailing out either.
You may also be interested in...
Corus Pharma: Experienced Help Found
Investors are buying into Corus, which is betting that it can find value in anti-infectives and respiratory products that others discarded because of problematic clinical trials.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.